Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to $1.0 million.

  • SOPHiA GENETICS's Depreciation and Depletion fell 1128.47% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 1136.91%. This contributed to the annual value of $4.6 million for FY2024, which is 2412.94% down from last year.
  • Latest data reveals that SOPHiA GENETICS reported Depreciation and Depletion of $1.0 million as of Q3 2025, which was down 1128.47% from $942000.0 recorded in Q2 2025.
  • SOPHiA GENETICS's Depreciation and Depletion's 5-year high stood at $1.6 million during Q2 2023, with a 5-year trough of $432000.0 in Q2 2021.
  • Its 5-year average for Depreciation and Depletion is $1.0 million, with a median of $1.0 million in 2025.
  • In the last 5 years, SOPHiA GENETICS's Depreciation and Depletion skyrocketed by 11875.0% in 2022 and then crashed by 2894.9% in 2024.
  • Quarter analysis of 5 years shows SOPHiA GENETICS's Depreciation and Depletion stood at $922000.0 in 2021, then rose by 15.29% to $1.1 million in 2022, then rose by 10.07% to $1.2 million in 2023, then fell by 2.91% to $1.1 million in 2024, then decreased by 10.04% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $942000.0 for Q2 2025, and $985000.0 during Q1 2025.